Loading people...
Eyal Lifschitz is a Managing Partner and co-founder of Peregrine Ventures, a leading Israeli venture capital firm. He is a seasoned investor and entrepreneur with extensive experience in the medical device, digital health, and life sciences sectors.
Eyal Lifschitz primarily invests in early-stage Israeli companies within the medical device, digital health, and life sciences industries. He focuses on disruptive technologies with strong market potential and a clear path to addressing unmet medical needs.
Eyal Lifschitz works as a Managing Partner at Peregrine Ventures, a venture capital firm based in Israel.
Eyal Lifschitz stands as a cornerstone of the Israeli venture capital landscape, serving as a Managing Partner and co-founder of Peregrine Ventures. As one of Israel's most established and successful VC firms, Peregrine Ventures, under Lifschitz's leadership, has consistently focused on identifying and cultivating groundbreaking early-stage companies within the medical device, digital health, and broader life sciences sectors. His strategic vision and deep industry acumen have been instrumental in positioning Peregrine as a leader in healthcare technology investment.
At Peregrine Ventures, Eyal Lifschitz is not merely an investor; he is a hands-on partner who actively guides portfolio companies from inception through successful market entry and exit. His role encompasses leading investment rounds, shaping corporate strategy, and leveraging his extensive network to accelerate growth. He is particularly adept at recognizing disruptive technologies that address significant unmet medical needs, providing both capital and invaluable operational mentorship to founders.
Lifschitz's investment philosophy is deeply rooted in his rich entrepreneurial and operational background. Before co-founding Peregrine Ventures, he garnered significant experience as an entrepreneur himself. He was the CEO of VisionSense, a company specializing in advanced vision systems. Critically, he also co-founded Bio-Sense, a pioneering medical device company that developed innovative electrophysiology mapping systems, which was successfully acquired by Johnson & Johnson. This direct experience in building and scaling medical technology companies provides him with a unique perspective, enabling him to truly understand the challenges and opportunities faced by startup founders. Earlier in his career, he held various R&D and management positions at Elbit Medical Imaging, further solidifying his technical and managerial expertise. Eyal holds an MBA and a BSc in Electrical Engineering, providing a strong foundation for his analytical and strategic capabilities.
Peregrine Ventures' impressive track record reflects Lifschitz's discerning eye for innovation. Notable investments and successful exits under his guidance include Valtech Cardio, a company developing transcatheter mitral and tricuspid valve repair and replacement solutions, which was acquired by Edwards Lifesciences. Another significant success was Eximo Medical, a developer of single-use atherectomy and thrombectomy systems, acquired by AngioDynamics. The portfolio also features promising companies like Memic Innovative Surgery, which is revolutionizing robotic surgery, and CartiHeal, focused on cartilage regeneration. These examples underscore his commitment to backing companies that not only promise significant financial returns but also have the potential to profoundly impact patient care globally.
Eyal Lifschitz continues to be a driving force in fostering innovation within the Israeli healthcare technology ecosystem. His blend of operational experience, strategic investment prowess, and unwavering dedication to advancing medical science makes him a pivotal figure for entrepreneurs seeking to transform the future of health.
Eyal Lifschitz is the Co-founder and Managing General Partner of Peregrine Ventures, a life sciences venture capital firm based in the Tel Aviv District, Israel. Before establishing the firm in 2001, he operated as a serial entrepreneur, founding medical technology companies such as ECR and PharmaSys, which was acquired by Elan Corp. He also co-founded Visioncare Ophthalmic Technologies and served as a director at Given Imaging. At Peregrine Ventures, Lifschitz oversees a portfolio managing over $600 million in assets, including a $300 million late-stage growth fund closed in 2020. He directs investments and holds board seats for companies like Valtech Cardio and CartiHeal, which Smith+Nephew acquired for up to $330 million in 2023. His current focus remains on funding and scaling early to late-stage innovations across the medical device, digital health, and biotechnology sectors.
